CytomX Therapeutics Inc banner

CytomX Therapeutics Inc
NASDAQ:CTMX

Watchlist Manager
CytomX Therapeutics Inc Logo
CytomX Therapeutics Inc
NASDAQ:CTMX
Watchlist
Price: 4.56 USD Market Closed
Market Cap: $772.6m

Wall Street
Price Targets

CTMX Price Targets Summary
CytomX Therapeutics Inc

Wall Street analysts forecast CTMX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CTMX is 13.9 USD with a low forecast of 10.1 USD and a high forecast of 17.85 USD.

Lowest
Price Target
10.1 USD
121% Upside
Average
Price Target
13.9 USD
205% Upside
Highest
Price Target
17.85 USD
291% Upside
CytomX Therapeutics Inc Competitors:
Price Targets
FBIZ
First Business Financial Services Inc
24% Upside
LVS
Las Vegas Sands Corp
31% Upside
RLYB
Rallybio Corp
-3% Downside
LAND
Gladstone Land Corp
13% Upside

Revenue
Forecast

28% / Year
Past Growth
-12% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
28% / Year
Past Growth
-12% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

For the last 11 years the compound annual growth rate for CytomX Therapeutics Inc's revenue is 28%. The projected CAGR for the next 3 years is -12%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-75%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-75%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CTMX's stock price target?
Price Target
13.9 USD

According to Wall Street analysts, the average 1-year price target for CTMX is 13.9 USD with a low forecast of 10.1 USD and a high forecast of 17.85 USD.

What is CytomX Therapeutics Inc's Revenue forecast?
Projected CAGR
-12%

For the last 11 years the compound annual growth rate for CytomX Therapeutics Inc's revenue is 28%. The projected CAGR for the next 3 years is -12%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett